A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Inclusion criteria

• Has facial acne vulgaris with all of the following:

• 20 to 50 inflammatory lesions (papules and/or pustules) on the face.
• 25 to 100 non-inflammatory lesions (open and closed comedones) on the face.
• IGA score of moderate (3) to severe (4).
• No more than two active nodules on the face.
• Willing to use only the supplied non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study

Exclusion criteria

• Female who is pregnant or lactating, or is planning a pregnancy during the study.
• Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face that could interfere with the clinical evaluations.
• Facial hair (eg, beard, mustache, etc.) that could interfere with the clinical evaluations.
• Sunburn on the face.
• Severe systemic disease as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of the results.
• Subjects who have a documented history of any of the following:

• Allergy to tetracycline-class antibiotics or to any ingredient in the study drug.
• Pseudomembranous colitis or antibiotic-associated colitis.
• Hepatitis or clinically significant liver damage or clinically significant renal impairment.
• Known or suspected premalignant or malignant disease (excluding successfully treated skin cancers).
• Subjects who have used the following medications:

Within 1 week prior to randomization:

• Medicated facial cleansers on the face.
• Topical acne treatments on the face (other than those listed below).

Within 4 weeks prior to randomization:

• Topical retinoids on the face.
• Topical anti-inflammatories and/or corticosteroids on the face.
• Topical corticosteroids on body areas other than the face for more than 15 consecutive days and on more than 10% of the body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed for short term use (≤15 consecutive days).
• Systemic antibiotics.
• Systemic acne treatments.

Within 12 weeks prior to randomization:

• Systemic retinoids.
• Systemic corticosteroids (Note: Intranasal and inhaled corticosteroids may be used throughout the study if the subject is on a stable dose).
• Use of sauna during the 2 weeks prior to randomization.
• Epilation of the face within 2 weeks prior to randomization.
• Folliculitis on the face.
• Documented history of depression that is not, in the opinion of the Investigator, currently adequately controlled with medication